- $43.10m
- $95.50m
- $1.16bn
- 20
- 56
- 42
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47.5% | ||
| Return on Equity | -425.5% | ||
| Operating Margin | -47.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 280.67 | 514.89 | 1,513.03 | 751.16 | 1,160.8 | 1,001.12 | 1,105.01 | 54.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeueHealth, Inc. is a value-driven healthcare company. The Company’s segments include NeueCare and NeueSolutions. NeueCare segment is a value-driven care delivery business that manages risk in partnership with external payors and serves all populations across the ACA Marketplace, Medicare, and Medicaid. NeueCare delivers in-person and virtual clinical care through its 73 owned primary care clinics within an integrated care delivery system. Its integrated system of care includes embedded pharmacy, laboratory, radiology, and population health focused specialty services. It offers a one-stop-shop for consumers providing primary care, behavioral health, rotating specialties, pharmacy, radiology, and laboratory services, many times at a single location. NeueSolutions segment is a provider enablement business that includes a suite of technology, services, and clinical care solutions that empower providers. NeueSolutions serves approximately 62,000 value-based care consumers.
Directors
- Robert Sheehy CHM (63)
- G. Mike Mikan PRE (50)
- Tomas Valdivia CFD (59)
- Catherine Smith CFO (55)
- Simeon Schindelman CEX (58)
- Sam Srivastava CEX (53)
- Keith Nelsen GCN (57)
- Kedrick Adkins IND (68)
- Naomi Allen IND (47)
- Jeffrey Folick IND (73)
- Linda Gooden IND (68)
- Jeffrey Immelt IND (65)
- Manuel Kadre IND (55)
- Stephen Kraus IND (44)
- Mohamad Makhzoumi IND (41)
- Adair Newhall IND (42)
- Andrew Slavitt IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 7th, 2015
- Public Since
- June 24th, 2021
- No. of Shareholders
- 175
- No. of Employees
- 1,252
- Sector
- Insurance
- Industry
- Financials
- Exchange
New York Stock Exchange- Shares in Issue
- 8,224,541
- Address
- 9250 Nw 36Th Street, Suite 420, DORAL, 33178
- Web
- https://www.neuehealth.com/
- Phone
- +1 6122381321
- Auditors
- Deloitte & Touche LLP
Upcoming Events for NEUE
Similar to NEUE
Aegon
New York Stock Exchange
Aflac
New York Stock Exchange
Allstate
New York Stock Exchange
Ambac Financial
New York Stock Exchange
American Financial
New York Stock Exchange
FAQ
What is the Neuehealth share price?
As of Today at 22:16 UTC, shares in Neuehealth are trading at $5.15. This share price information is delayed by 15 minutes.
How has the Neuehealth share price performed this year?
Shares in Neuehealth last closed at $5.15 and the price had moved by -62.6% over the past 365 days. In terms of relative price strength the Neuehealth share price has underperformed the S&P500 Index by -70.24% over the past year.
What are the analyst and broker recommendations for Neuehealth?
The overall consensus recommendation for Neuehealth is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Neuehealth dividend yield?
Neuehealth does not currently pay a dividend.
Does Neuehealth pay a dividend?
Neuehealth does not currently pay a dividend.
When does Neuehealth next pay dividends?
Neuehealth does not currently pay a dividend.
How do I buy Neuehealth shares?
To buy shares in Neuehealth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neuehealth?
As of the previous close price of $5.15, shares in Neuehealth had a market capitalisation of $42.36m.
Where are Neuehealth shares listed?
Here are the trading details for Neuehealth:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: NEUE
What kind of share is Neuehealth?
Based on an overall assessment of its quality, value and momentum Neuehealth is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neuehealth share price forecast for 2024?
The analyst consensus target price for shares in Neuehealth is $20.67. That is 301.36% above the last closing price of $5.15.
Analysts covering Neuehealth currently have a consensus Earnings Per Share (EPS) forecast of -$15.39 for the next financial year.
What is the trend in the Neuehealth share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuehealth. Over the past six months, its share price has underperformed the S&P500 Index by -14.45%.
As of the last closing price of $5.15, shares in Neuehealth were trading -28.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neuehealth PE Ratio?
The Neuehealth PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neuehealth?
Neuehealth's management team is headed by:
- Robert Sheehy - CHM
- G. Mike Mikan - PRE
- Tomas Valdivia - CFD
- Catherine Smith - CFO
- Simeon Schindelman - CEX
- Sam Srivastava - CEX
- Keith Nelsen - GCN
- Kedrick Adkins - IND
- Naomi Allen - IND
- Jeffrey Folick - IND
- Linda Gooden - IND
- Jeffrey Immelt - IND
- Manuel Kadre - IND
- Stephen Kraus - IND
- Mohamad Makhzoumi - IND
- Adair Newhall - IND
- Andrew Slavitt - IND